Clinical Cost-Effectiveness as a Novel Metric for Steering Emerging Medical Technology
Background: Steering an emerging medical technology involves making decisions under uncertainty. Localized drug delivery (LDD) is an emerging medical technology that may be useful in treating epilepsy, which is burdensome and difficult to clinically manage. Costeffectiveness analysis (CEA) is a mode...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Published: |
Massachusetts Institute of Technology
2025
|
| Online Access: | https://hdl.handle.net/1721.1/157969 |